US EditionPublished • loading... • Updated
Colossal Biosciences Buys Cloning Leader Viagen
Colossal Biosciences acquired Viagen Pets and Equine to combine cloning expertise and de-extinction goals, enabling breakthroughs with 80% cloning success rates in endangered species.
- Colossal Biosciences acquired Viagen Pets and Equine, marking Colossal's first acquisition since its 2021 launch with Viagen operating as a wholly-owned subsidiary.
- Earlier this year, Colossal Biosciences made headlines after de-extincting dire wolves following 12,500 years of extinction and had drawn attention in 2021 for plans to bring back the woolly mammoth.
- Viagen Pets and Equine, founded 2002 , has cloned 15 species including black-footed ferret and Przewalski's horse, optimized protocols with 80% success, and biobanked over 40 species including 22 threatened.
- Viagen President Blake Russell will continue to run operations after a 25-year career, and Ben Lamm, Founder and CEO of Colossal, said the merger advances biodiversity-saving efforts.
- Combining Viagen's cloning stack with Colossal's resources could scale conservation cloning, as Viagen's cryopreservation expertise will fuel Colossal's Bio Vaults and leverage Roslin Institute of Edinburgh licensing.
Insights by Ground AI
13 Articles
13 Articles
De-extinction 'decacorn' Colossal opens wallet for first acquisition - Dallas Business Journal
Colossal announced Nov. 4 it has acquired ViaGen Pets and Equine, a firm that’s considered a leader in animal cloning. This deal marks a union between two life sciences companies that have a similar goal of preserving endangered species through the use of cloning technology.
·United States
Read Full Article
Coverage Details
Total News Sources13
Leaning Left2Leaning Right0Center6Last UpdatedBias Distribution75% Center
Bias Distribution
- 75% of the sources are Center
75% Center
L 25%
C 75%
Factuality
To view factuality data please Upgrade to Premium
